Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > New week, day, month, post, threads

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Apr 01, 2024 6:06pm

120 Views

Post# 35963796

RE:RE:RE:RE:RE:New week, day, month, post, threads

In 2004, a nonpathogenic enteric cytopathic human orphan virus (Rigvir) was approved in Latvia for the treatment of melanoma, which was the first OV to be approved for cancer treatment worldwide. A genetically modified recombinant human adenovirus type 5, Oncorine or H101, was approved for marketing in China in 2005.

In 2015, the Food and Drug Administration (FDA) of USA approved T-vec (Talimogene laherparepvec, Imlygic) for the topical treatment of unresectable skin, subcutaneous and lymph node lesions in patients with recurrent melanoma after the first surgery. This was the first OV drug approved by the FDA. Subsequently, T-vec was approved in Europe and Canada, marking a milestone in oncolytic virotherapy for cancer. On June 11, 2021, Daiichi Sankyo Company Limited of Japan announced that their oncolytic herpes simplex virus (HSV) Delytact (TeserpatureV /G47) has received conditional, time-limited approval from Japan's Ministry of Health, Labor and Welfare (MHLW) for the treatment of malignant glioma. [ Daiichi Sankyo is the originator of the antibody drug conjugate (ADC) known as Enhertu and in-licensed by AstraZeneca for the treatment in breast cancer].This was the fourth OV approved worldwide and the first to be approved for malignant glioma . There are currently four OVs that have been approved globally.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472052/